Pathologic complete response after neoadjuvant paclitaxel and carboplatin chemotherapy for stage II-III breast cancer: A community cancer center experience.

被引：0
|
作者：
Belur, Anuradha
Raajasekar, Arun Kumar Arumugam
Burdette-Radoux, Susan
机构：
[1] Maimonides Canc Ctr, Brooklyn, NY USA
[2] Maimonides Hosp, Brooklyn, NY 11219 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 28期
关键词：
D O I：
10.1200/jco.2015.33.28_suppl.43
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
43
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Neoadjuvant chemotherapy for stage II-III breast cancer: a single-center experience
    Zaher, Haidi Abd El
    Fathy, Hamada
    Abozeid, Mohamed
    Faisal, Mohammed
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [2] Paclitaxel and cisplatin as neoadjuvant chemotherapy in bladder cancer (stage II-III).
    Quintero-Aldana, G
    Vázquez-Estevez, S
    Sabin-Dominguez, P
    Mel-Lorenzo, JR
    Bermudez-Cancelo, JM
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S50 - S50
  • [3] Role of Postmastectomy Radiation After Neoadjuvant Chemotherapy in Stage II-III Breast Cancer
    Fowble, Barbara L.
    Einck, John P.
    Kim, Danny N.
    McCloskey, Susan
    Mayadev, Jyoti
    Yashar, Catheryn
    Chen, Steven L.
    Hwang, E. Shelley
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 83 (02): : 494 - 503
  • [4] Survivin As a Predictive Biomarker of Complete Pathologic Response to Neoadjuvant Chemotherapy in Patients With Stage II and Stage III Breast Cancer
    Petrarca, Cristiane Rios
    Brunetto, Andre T.
    Duval, Vinicius
    Brondani, Adriana
    Carvalho, Gisele Pereira
    Garicochea, Bernardo
    CLINICAL BREAST CANCER, 2011, 11 (02) : 129 - 134
  • [5] Predictors of Pathologic Complete Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer: the Impact of Chemotherapeutic Regimen
    Nwaogu, Iheoma
    Fayanju, Oluwadamilola M.
    Yan, Yan
    Jeffe, Donna B.
    Margenthaler, Julie A.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : 86 - 87
  • [6] Neoadjuvant chemotherapy for stage II–III breast cancer: a single-center experience
    Haidi Abd El Zaher
    Hamada Fathy
    Mohamed Abozeid
    Mohammed Faisal
    World Journal of Surgical Oncology, 21
  • [7] Neoadjuvant combination for stage II-III breast cancer
    Bagchi, Sanjit
    LANCET ONCOLOGY, 2007, 8 (07): : 579 - 579
  • [8] Nab-paclitaxel and carboplatin with or without trastuzumab (trast) as part of neoadjuvant chemotherapy (NCT) in patients (pts) with stage II-III breast cancer (BC)
    Paz, I. B.
    Lau, S.
    Garberoglio, C.
    Luu, T. H.
    Chung, C. T.
    Mortimer, J.
    Wagman, L.
    Shen, J.
    Frankel, P.
    Somlo, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Effect of neoadjuvant pertuzumab-containing regimens on pathologic complete response rates in stage II-III HER2-neu positive breast cancer: A retrospective, single institutional experience.
    Murthy, Rashmi Krishna
    Fujii, Takeo
    Hess, Kenneth R.
    Raghavendra, Akshara Singareeka
    Lim, Bora
    Barcenas, Carlos Hernando
    Zhang, Hong Amy
    Gregor, Mariana Chavez-Mac
    Mittendorf, Elizabeth Ann
    Litton, Jennifer Keating
    Giordano, Sharon Hermes
    Thompson, Alastair Mark
    Valero, Vicente
    Tripathy, Debu
    Ueno, Naoto T.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Metformin with neoadjuvant chemotherapy in stage II-III breast cancer: A phase II clinical trial
    Azazy, H. A.
    Gado, N. M.
    Salem, D. A.
    El-Ghamry, W. R.
    ANNALS OF ONCOLOGY, 2020, 31 : S323 - S324
12345